LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.27 2.42

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.23

Máximo

1.31

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+60% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-24M 78M
Apertura anterior	-1.15
Cierre anterior	1.27

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 mar 2026, 23:39 UTC

Acciones populares

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar 2026, 23:20 UTC

Ganancias

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar 2026, 21:43 UTC

Ganancias

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar 2026, 23:24 UTC

Charlas de Mercado

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar 2026, 22:30 UTC

Ganancias

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar 2026, 22:30 UTC

Ganancias

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar 2026, 22:30 UTC

Ganancias

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar 2026, 22:13 UTC

Ganancias

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Ganancias

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Ganancias

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar 2026, 22:04 UTC

Charlas de Mercado

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar 2026, 21:53 UTC

Ganancias

Lithium Americas 4Q Rev $66.8M >LAC

4 mar 2026, 21:53 UTC

Ganancias

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar 2026, 21:52 UTC

Ganancias

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:50 UTC

Ganancias

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 mar 2026, 21:48 UTC

Ganancias

Webull 4Q Rev $165.2M >BULL

4 mar 2026, 21:48 UTC

Ganancias

Webull 4Q EPS 1c >BULL

4 mar 2026, 21:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 mar 2026, 21:45 UTC

Charlas de Mercado

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar 2026, 21:40 UTC

Ganancias

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:36 UTC

Noticias de Eventos Importantes

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar 2026, 21:27 UTC

Ganancias

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:17 UTC

Charlas de Mercado

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar 2026, 21:16 UTC

Ganancias

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar 2026, 21:15 UTC

Ganancias

Broadcom 1Q EPS $1.50 >AVGO

4 mar 2026, 21:15 UTC

Ganancias

Broadcom 1Q Net $7.35B >AVGO

4 mar 2026, 21:15 UTC

Ganancias

Broadcom 1Q Rev $19.31B >AVGO

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

60% repunte

Estimación a 12 Meses

Media 2 USD 60%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.